What criteria would you use to decide between trastuzumab-deruxtecan and sacituzumab govitecan in HER2 low metastatic TNBC given TDx approval in HER2 low breast cancer?

Topics: Breast Cancer • Medical Oncology • Breast Cancer, Metastatic

Answer from: Medical Oncologist at Community Practice

There are currently unfortunately no biomarkers to select participants for antibody drug conjugate therapies, including sacituzumab and trastuzumab deruxtecan for HER2 low metastatic TNBC. The studies evaluating sacituzumab govitecan and trastuzumab deruxtecan had different I/E criteria, includ...

Comments

Medical Oncologist at Sky Lakes Medical Center
Excellent insight.

Medical Oncologist at University of Texas MD Anderson Cancer Center
Agree with the answer from Dr. @Zahi Mitri. Patien...

Answer from: Medical Oncologist at Community Practice

I think this question can now be broadened out beyond TNBC to ER+Her2- metastatic disease. While in TNBC the evidence supports (I think) using sacituzumab prior to leaning on TDXd, I would personally argue for using TDXd prior to trying sacituzumab in HR+ disease based on response rates and benefit ...

Related Questions